Skip to main content
PolicySpeak
← All files
LS

LIF Sweden

Industry association · Sweden

3
positions filed
in the 583 files tracked
2
legislative files
of 583 tracked
2
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Track LIF in PolicySpeak: request access →

Work at LIF Sweden? so we know who speaks for it.

Follow the files LIF Sweden engages with

One email on Tuesdays when a new position is filed on these 2 files, from LIF Sweden or from anyone else on them. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

LIF Sweden filed 3 positions between 3 Feb 2023 and 2 Nov 2023, across 2 of the 583 legislative files tracked here, attaching a full position paper 2 times.

What they argued

Medicinal products for human usefiled 2 Nov 2023PDFsource

The LIF welcomes the Commission’s initiative for a modernised regulatory framework for medicines that can be more easily adapted to technological and medical developments. The LIF considers that the Commission’s objective of creating more equal access to new medicines between EU Member States is important. On the other hand, the proposal contains several elements to which Lif has strong objections.

Filed in Swedish · English published by the European Commission

Medicinal products for human usefiled 2 Nov 2023PDFsource

Replies to the EU Commission deadline 7 November 2023 Lif welcomes the Commission’s initiative for a modernised regulatory framework for medicines that can be more easily adapted to technological and medical developments. The LIF considers that the Commission’s objective of creating more equal access to new medicines between EU Member States is important.

Filed in Swedish · English published by the European Commission

Fees and charges payable to the European Medicines Agencyfiled 3 Feb 2023source

Lif Sweden is the trade association for the research-based pharmaceutical industry in Sweden. Lif welcomes the opportunity to comment on the EU Commissions EMA fees proposal. The up-coming revision of the EU regulatory system is an opportunity to make the system faster, more efficient and flexible and thereby strengthen EU global competitiveness.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put LIF Sweden next to another organization. Same files, same register facts, side by side. Compare →

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.

Showing 5 of 6.

Is this your organization?

Everything on this page comes from LIF Sweden’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.